Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0001209191-24-003410 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-15 | 2024-02-13+ | RXRX | Secora Michael | CFO | S - Sale+OE | $10.16 | -50.0K | 1.19M | -4% | -$507.8K |
| DM | 2024-02-15 | 2024-02-13+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 1.20M | +7% | +$166.5K |
| DM | 2024-02-15 | 2024-02-13+ | RXRX | Secora Michael | CFO | M - OptEx | $0.00 | -75.0K | 997.6K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-02-13 | S | D | 25,000 | $9.86 | 1,173,851 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $9.635 to $10.16 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2024-02-14 | M | A | 37,500 | $2.22 | 1,211,351 | D | — | — | |
| 3 | Common | Class A Common Stock | 2024-02-13 | M | A | 37,500 | $2.22 | 1,198,851 | D | — | — | |
| 4 | Common | Class A Common Stock | 2024-02-14 | S | D | 23,933 | $10.43 | 1,187,418 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $9.92 to $10.905. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 5 | Common | Class A Common Stock | 2024-02-14 | S | D | 1,067 | $10.98 | 1,186,351 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $10.925 to $11.015. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-02-14 | M | D | 37,500 | $0.00 | 960,135 | D | $2.22 · — to 2030-03-03 | 37,500 Class A Common Stock | (F6) The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-02-13 | M | D | 37,500 | $0.00 | 997,635 | D | $2.22 · — to 2030-03-03 | 37,500 Class A Common Stock | (F6) The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. |